Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.53 - $50.99
Previous CloseN/A
Volume41.45K
Average Volume (3M)426.37K
Market Cap
$2.98B
Enterprise Value$2.42B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Feb 26, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding76,239,600
10 Day Avg. Volume437,000
30 Day Avg. Volume426,366
Standard Deviation0.17
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.47
Enterprise Value/Ebitda-9.59
Forecast
1Y Price Target
$55.83Price Target Upside40.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Xenon News
PremiumCompany Announcements
Xenon Pharmaceuticals to Announce Q4 and Full Year 2024 Financial Results
PremiumCompany Announcements
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role
PremiumCompany Announcements
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones
PremiumCompany Announcements
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference
---
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsXenon stands to receive milestones and royalties from a collaboration with Neurocrine, adding long-term value and potential upside.
EarningsExpectations are for the stock to move into the $45-50 range ahead of the epilepsy data event.
Product PerformanceAzetukalner has demonstrated encouraging Ph. II data in FOS driving a 52.8% reduction in seizure frequency from baseline vs. an 18.2% change in the placebo group.
Bears Say
Clinical Study LimitationsXenon expects results from the small investigator-sponsored study of azetulkaner in MDD but given the lack of appropriate powering for the key cognitive endpoints, it doesn’t necessarily expect a read-through to the company’s planned larger Phase 3 program.
Clinical Trial ChallengesThe trial results were mixed as statistical significance wasn’t achieved on the primary endpoint on the MADRS scale, although was achieved on multiple key secondaries including the HAM-D.
Market ConcernsThe data disclosure from the investigator-led study in MDD is viewed by some investors as an overhang on the stock.
---
Ownership Overview
0.16% Insiders
30.50% Mutual Funds
62.23% Other Institutional Investors
5.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $35.53 and its highest was $50.99 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.98B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Nov 12, 2024. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.816 by $0.006.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -0.86.
How many shares outstanding does Xenon have?
Xenon has 76,239,600 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.816. Following the earnings report the stock price went down -3.273%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
---
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.83 (40.52% Upside)
$55.83 (40.52% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $971.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.66%
12-Months-Change
Fundamentals
Return on Equity
-26.75%
Trailing 12-Months
Asset Growth
24.56%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
---
XENE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The overall sentiment of the earnings call is positive, with significant progress in clinical programs, strong financial health, and anticipation of important milestones in 2025. However, there are concerns about decreased cash reserves and potential enrollment challenges.Read More>---
XENE Stock 12 Month Forecast
Average Price Target
$55.83
▲(40.52% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering XENE
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+35.09%
assigned a buy rating 3 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +35.09% per trade.
---